WJA
AST

Williams Jones & Associates’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Williams Jones & Associates’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-30,100
Closed -$19K – 424
2018
Q4 		$19K Hold
30,100
– – ﹤0.01% 392
2018
Q3 		$39K Hold
30,100
– – ﹤0.01% 439
2018
Q2 		$41K Buy
30,100
+10,000
+50% +$15.3K ﹤0.01% 435
2018
Q1 		$29K Buy
20,100
+5,000
+33% +$10.4K ﹤0.01% 444
2017
Q4 		$34K Hold
15,100
– – ﹤0.01% 432
2017
Q3 		$51K Hold
15,100
– – ﹤0.01% 425
2017
Q2 		$54K Hold
15,100
– – ﹤0.01% 403
2017
Q1 		$51K Hold
15,100
– – ﹤0.01% 399
2016
Q4 		$69K Hold
15,100
– – ﹤0.01% 367
2016
Q3 		$64K Buy
+15,100
New +$48.8K ﹤0.01% 386

Williams Jones & Associates's AST Position: Q1 2019 in Review

Williams Jones & Associates sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 30,100 shares — an estimated $19K sold.

Williams Jones & Associates first reported a position in AST in Q3 2016 and held it in 10 quarters. The position peaked at $69K in Q4 2016. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.

  • Williams Jones & Associates reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
  • Williams Jones & Associates sold 30,100 Asterias Biotherapeutics Inc. Series A shares in Q1 2019, an estimated $19K.
  • Williams Jones & Associates first reported a position in Asterias Biotherapeutics Inc. Series A in Q3 2016 and held it in 10 quarters.
  • Williams Jones & Associates's Asterias Biotherapeutics Inc. Series A position peaked at $69K in Q4 2016.
  • 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.

Based on Williams Jones & Associates's 13F filing for Q1 2019, filed 14 May 2019.